This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
doi: 10.1530/EJE-18-0608.) ERN / Endo ERN Existing networks or registries and biobanks (Adrenal (MTG1) / Existing networks) European Society of Endocrinology Clinical Practice Guideline on the management of Adrenal Incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors (ESE Clinical Practice Guideline on the management of Adrenal Incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors) European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma (BJS, Volume 104, Issue 4, March 2017, Pages 358–376) ENSAT registry-based randomized clinical trials for adrenocortical carcinoma (Eur J Endocrinol. 2021 Feb;184(2):R51-R59. doi: 10.1530/EJE-20-0800.)
== Natural sources of alkylresorcinols == Alkylresorcinols are relatively rare in nature and are reported to be found in fungi, bacteria, and some lower and higher plants. DB-2073 is an antibiotic isolated from the broth culture of Pseudomonas sp. They are also the main constituents of the outer shell of the cyst of Azotobacter. Among the plant sources, the shell oil of cashew nut (Anacardium occidentale L.) has the highest amount of ARs, which consists of 20% phenolic lipids. Moreover, ARs were found in the peels and pulp of peas (Pisum sativum L.), pulp and leaves of ginkgo (Ginkgo biloba L.), pulp and peels of mango (Mangifera indica L.), and in some cereals. In the case of cereals, the hyaline layer, inner pericarp, and testa showed the highest amounts of AR.
== Treatment == Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.
Stanozolol (abbrev. Stz), sold under many brand names, is a synthetic androgen and anabolic steroid (AAS) medication derived from dihydrotestosterone (DHT). It is used to treat hereditary angioedema. It was developed by American pharmaceutical company Sterling-Winthrop in 1962, and has been approved by the U.S. Food and Drug Administration for human use, though it is no longer marketed in the United States. It is also used in veterinary medicine. Stanozolol has mostly been discontinued, and remains available in only a few countries. It is given by mouth in humans or by injection into muscle in animals. Unlike most AAS, stanozolol is not esterified and is sold as an aqueous suspension, or in oral tablet form. The drug has a high oral bioavailability, due to a C17α alkylation which allows the hormone to survive first-pass liver metabolism when ingested. It is because of this that stanozolol is also sold in tablet form. Stanozolol is one of the AAS commonly used as performance-enhancing drugs and is banned from use in sports competition under the auspices of the World Anti-Doping Agency (WADA). It is an anabolic steroid that is known to have a diuretic effect. Additionally, stanozolol has been highly restricted in US horse racing.
13 March Kon Sitiu and Kon Bobanh, two Montagnard villages in Kon Tum Province, were raided by VC; 15 persons killed; 23 kidnapped, two of whom were later executed; three long-houses, a church and a school burned. A hamlet chief is beaten to death. Survivors said that the VC explained that: "We are teaching you not to cooperate with the government."
Sources: en.wikipedia.org
Mirzayanov provided the first description of these agents. Dispersed in an ultra-fine powder instead of a gas or a vapour, they have unique qualities. A binary agent was then created that would mimic the same properties but would either be manufactured using materials which are not controlled substances under the CWC, or be undetectable by treaty regime inspections. The most potent compounds from this family, Novichok-5 and Novichok-7, are supposedly around five to eight times more potent than VX. The "Novichok" designation refers to the binary form of the agent, with the final compound being referred to by its code number (e.g. A-232). The first Novichok series compound was in fact the binary form of a known V-series nerve agent, VR, while the later Novichok agents are the binary forms of compounds such as A-232 and A-234.
== The influence of age: age-structured models == Age has a deep influence on the disease spread rate in a population, especially the contact rate. This rate summarizes the effectiveness of contacts between susceptible and infectious subjects. Taking into account the ages of the epidemic classes
== History == Prior to the UGR's implementation, the U.S. military had several different types of rations used to feed service members in the rear or out of combat. Among them were the A-ration, consisting of fresh, refrigerated, or frozen food prepared in a kitchen and served in a mess, dining facility, or elsewhere; the B-ration, consisting of packaged, preserved foods prepared in a field kitchen; and the T-ration, a semi-perishable meal packaged, heated, and served in a tray pack similar to frozen meals; among others. This created issues for military cooks, who "had to order an average of 34 separate items for each meal, and could only hope that they arrived when needed", forcing them to manage logistics and administrative functions instead of solely food preparation. Around 1995, the U.S. military launched a modernization program to resolve this issue while also increasing the quality and decreasing the cost of existing rations. Research was headed by the U.S. Army Natick Soldier Research, Development and Engineering Center and the U.S. Army Quartermaster Center and School. In 1999, the UGR was created to simplify logistics and ensure all necessary ingredients were provided, combining elements and offerings of the A-ration, B-ration, T-ration, and commercial items. The UGR was initially trialed with the Army, with their first shipments received around 2000; the Air Force, Marine Corps, and Navy also began receiving UGRs at unspecified dates. The UGR-E was introduced in 2006. The UGR-B was phased out and replaced by the mostly similar UGR-M at an unspecified date.
Recent advancements on the nanoscale such as devices that fabricate both spherical and non-spherical droplets that are ultrafast and homogeneous mixed are being produced for large scale production of powdered particles in industrial applications. Monodispersed nanoparticles are also of great interest in catalyst fabrication. Many heterogeneous catalytic systems efficiencies rely on high surface areas of transition metal particles. Microfluidic techniques have been used to fabricate gold nanoparticles through the interfacial interaction of droplets containing gold chloride, hexane, and a reducing agent with a surrounding aqueous phase. This process can also control both the size and shape of nanoparticles/nanosheets with precision and high throughput compared to other methods such as physical vapor deposition. The use of droplets containing various materials such as silica or transition metals such as gold flowed through an immiscible oil phase has been shown to be effective in controlling both size of nanoparticles as well as pore size, which allows for design of efficient absorptive gas capture devices and heterogeneous catalysts. Monodispersed nanoparticles of gold and silver have been synthesized using gold and silver chloride droplets dosed with a reducing agent to cleave metal-ligand bonds, leading to the agglomeration of monodispersed metal nanoparticles which can be easily filtered out of solution.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.